Content » Vol 95, Issue 5

Investigative Report

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

Supplementary content
Appendix SI
Figure S1
Table SI
Table SII
Table SIII
Table SIV
Licenses
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.